secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptevo Therapeutics Inc. (APVO)
CIK:        0001671584
Form:       8-K
Filed at:   2026-05-27T20:05:16+00:00
Accession:  0001193125-26-241867
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptevo (APVO) partners with Niowave for radiopharma development; Niowave takes 7.9% equity stake
--------------------------------------------------------------------------------

- 50/50 strategic collaboration to develop up to three radiopharmaceutical oncology programs using Aptevo's multispecific platforms and Niowave's radioisotopes.
- Niowave made initial $500K equity investment for 7.9% stake; potential up to 19.99% through warrant exercises at $8.00/share.
- First program targets Nectin-4 with Actinium-225; proof-of-concept study to begin.
- Deal marks Aptevo's expansion into radiopharmaceuticals; Niowave's first therapeutic development investment.
- Niowave to supply radioisotopes if it opts out of collaboration; Aptevo retains development rights.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671584/000119312526241867/0001193125-26-241867-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671584/000119312526241867/apvo-20260525.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-241867

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer